ClinicalTrials.gg
Sign In

Retinopathy of Prematurity clinical trials

The registry lists 169 studies for Retinopathy of Prematurity across more than 10 countries. 27 are recruiting or about to start. 139 of them are mainly about Retinopathy of Prematurity (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Retinopathy of Prematurity studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
98
Status unknown
23
Recruiting
19
Terminated
10
Not yet recruiting
7
Withdrawn
5

Phase

Phase 2
26
Phase 3
23
Phase 4
11
Phase 1
9
Early Phase 1
1

Where

United States
51
Turkey
21
United Kingdom
14
Italy
14
Canada
12
Taiwan
11

Who runs them

NICHD Neonatal Research Network (5) · Novartis Pharmaceuticals (4) · Duke University (4) · Aristotle University Of Thessaloniki (4) · Bayer (4) · Asociación para Evitar la Ceguera en México (3) · Children's Hospital of Philadelphia (3) · Jaeb Center for Health Research (3)

Who develops what

Save this set

Every programme with a company-led study here in the last two years, whatever its size: 1 programme from 1 company, 1 with this as their studies’ main aim; 0 with a live phase 3 study; 0 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programmes

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 1 programme — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programmes. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorised original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licences, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Retinopathy of Prematurity studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Propranolol117
Fentanyl101
KH902 fusion protein101
Dexmedetomidine111
Faricimab111
Bevacizumab027
Ranibizumab036
Aflibercept033
Vitamin A003
Mecasermin rinfabate002

Drug classes tested here Angiogenesis inhibitors 1 open

Coming up

2phase 3 studies under way
7studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 7

Who these studies take

Of the 19 Retinopathy of Prematurity studies recruiting now, 7 (37%) set no upper age limit and 12 (63%) stop at 75 or younger. 19 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (21%) take healthy volunteers.

Recruiting studies that take each age, of 19
AgeWomenMen
108 (42%)8 (42%)
187 (37%)7 (37%)
307 (37%)7 (37%)
407 (37%)7 (37%)
507 (37%)7 (37%)
657 (37%)7 (37%)
757 (37%)7 (37%)
857 (37%)7 (37%)

Across all 169 studies, recruiting or not: 76% stop at 75 or younger and 76% at 65; 98% take children; 0% are for women only and 0% for men only; 18% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Retinopathy of Prematurity studies take

Of 30 interventional studies with no phase under Retinopathy of Prematurity, half reached primary completion within 14 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Interventional, no phase14 mo11–31 · 30 studies—14 mo12–31 · 28 studies
Observational31 mo16–53 · 25 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 15, 2026.

Started recruiting1

Studies

Recruiting first, then most recently updated. Showing 50 of 169. Browse all 169 → or search them.